FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
March 28 2024 - 9:31AM
FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage
biotechnology company with 150+ patents issued and pending with a
focus on the development of therapeutics and potential cures for
chronic diseases using fibroblasts and fibroblast-derived
materials, announced the filing of a patent application with the
United States Patent Office covering the use of FibroBiologics’
fibroblast cell-based technology for the potential treatment of
Lupus.
“Our scientists continue to explore clinical
opportunities to treat chronic diseases using fibroblast cells,
which are natural immune modulators. Successfully leveraging
fibroblasts to achieve a durable immune modulation may serve as a
potential treatment for Lupus, a debilitating autoimmune disease,”
noted Founder & CEO of FibroBiologics, Pete O’Heeron.
“The immune modulation capacity of fibroblasts
shows early promise in effectively regulating the expansion of
pathogenic immune cells and their expression of harmful levels of
cytokines, chemokines, growth factors, and complement factors.
Fibroblast cells may offer a broad range of potential clinical
benefits for patients suffering from chronic disease,” added Chief
Scientific Officer of FibroBiologics, Hamid Khoja, Ph.D.
For more information, please visit FibroBiologics’
website or email FibroBiologics at:
info@fibrobiologics.com.
Cautionary Statement Regarding
Forward-Looking Statements
This communication contains "forward-looking
statements" as defined in the Private Securities Litigation Reform
Act of 1995. Forward-looking statements include information
concerning the potential of fibroblasts to treat Lupus, the immune
modulation capacity of fibroblasts, and the potential of
fibroblasts to offer clinical benefits for patients suffering from
chronic disease. These forward-looking statements are based on
FibroBiologics' management's current expectations, estimates,
projections and beliefs, as well as a number of assumptions
concerning future events. These forward-looking statements are not
guarantees of future performance, conditions or results, and
involve a number of known and unknown risks, uncertainties,
assumptions and other important factors, many of which are outside
FibroBiologics' management's control, that could cause actual
results to differ materially from the results discussed in the
forward-looking statements, including those set forth under the
caption "Risk Factors" and elsewhere in FibroBiologics' annual,
quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form
8-K) as filed or furnished with the SEC and any subsequent public
filings. Copies are available on the SEC's
website, www.sec.gov. These risks, uncertainties, assumptions
and other important factors include, but are not limited to: (a)
risks related to FibroBiologics' liquidity and its ability to
maintain capital resources sufficient to conduct its business; (b)
expectations regarding the initiation, progress and expected
results of our R&D efforts and preclinical studies; (c) the
unpredictable relationship between R&D and preclinical results
and clinical study results; and (d) the ability of FibroBiologics
to successfully prosecute its patent applications. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and FibroBiologics assumes no obligation and, except as required by
law, does not intend to update, or revise these forward-looking
statements, whether as a result of new information, future events,
or otherwise. FibroBiologics gives no assurance that it will
achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a cell
therapy and regenerative medicine company developing a pipeline of
treatments and seeking potential cures for chronic diseases using
fibroblast cells and fibroblast-derived materials. FibroBiologics
holds 150+ US and internationally issued patents/patents pending
across various clinical pathways, including disc degeneration,
orthopedics, multiple sclerosis, wound healing, reversing organ
involution, and cancer. FibroBiologics represents the next
generation of medical advancement in cell therapy. For more
information, visit www.FibroBiologics.com.
General
Inquiries:info@fibrobiologics.com
Investor Relations:Nic Johnson or Harrison
Seidner, Ph.D.Russo
Partners212-845-4242fibrobiologicsIR@russopr.com
Media Contact:Liz PhillipsRusso Partners(347)
956-7697Elizabeth.phillips@russopartnersllc.com
FibroBiologics (NASDAQ:FBLG)
Historical Stock Chart
From May 2024 to Jun 2024
FibroBiologics (NASDAQ:FBLG)
Historical Stock Chart
From Jun 2023 to Jun 2024